E2V.L Share News (E2V)

Electronic components supplier e2v Technologies says that its figures for the year to March 2011 will be ahead of expectations. First half trading was significantly ahead of the same time last year thanks to overdue orders following industrial action. Underlying revenues were maintained. Radiotherapy, machine vision products and microprocessors for the Eurofighter were the strongest areas. The order book is worth £167m, with £147m of orders for delivery in the next 12 months. Net debt was £40m at the end of September 2010.Interim figures will be published on 15 November.A number of trades worth around £5,000 each appear to have pushed up the Ark Therapeutics share price even though there is no news from the pharma company. Network Technology continues to fall ahead of leaving the market on 29 October. AEA Technology is also continuing to fall after last week's US acquisition and deeply discounted fundraising at 5p a share. FTSE TechMARK - RisersArk Therapeutics (AKT) 5.60p +27.27%Vernalis (VER) 50.00p +10.53%Optos (OPTS) 103.50p +4.34%RM Group (RM.) 169.00p +4.32%SDL International (SDL) 612.00p +3.73%NXT (NTX) 3.63p +3.71%Imagination Technologies (IMG) 415.60p +3.67%E2V Technologies (E2V) 98.50p +3.43%BATM Advanced (BVC) 23.50p +3.35%Electronic Data Processing (EDP) 46.50p +2.20%FTSE TechMARK - FallersNetwork Technology (NTY) 525.00p -20.75%AEA Technology (AAT) 6.60p -16.08%Emblaze (BLZ) 49.00p -3.16%KCOM Group (KCOM) 51.50p -2.83%Kewill (KWL) 102.00p -2.39%Sepura (SEPU) 42.00p -2.33%Skyepharma (SKP) 38.50p -2.18%Phytopharm (PYM) 7.93p -1.98%Asterand (ATD) 13.00p -1.89%Innovation Group (TIG) 13.00p -1.89%